Bio Impact Capital LLC Phathom Pharmaceuticals, Inc. Transaction History

Bio Impact Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$6.99 - $10.71 $1.48 Million - $2.27 Million	-212,332 Reduced 75.21%	70,000 $639,000
Q2 2023 Aug 14, 2023	BUY	$7.28 - $14.32 $507,539 - $998,347	69,717 Added 32.79%	282,332 $4.04 Million
Q1 2023 May 12, 2023	BUY	$6.19 - $12.36 $103,205 - $206,078	16,673 Added 8.51%	212,615 $1.52 Million
Q4 2022 Feb 14, 2023	BUY	$9.18 - $11.53 $24,014 - $30,162	2,616 Added 1.35%	195,942 $2.2 Million
Q1 2022 May 13, 2022	BUY	$11.55 - $20.06 $2.23 Million - $3.88 Million	193,326 New	193,326 $2.63 Million

150

65.3M

1.15M

170K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $575M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Bio Impact Capital LLC with notifications on news.